Chugai and BioComber reach patent agreement for PURESYSTEM

Chugai and Biocomber have executed a license agreement on a patent owned by BioComber, it has been announced.

As part of the contract, Chugai will use PURESYSTEM – which is a reconstituted Escherichia coli in vitro translation system owned by BioComber – to boost its drug discovery efforts into antibodies and other substances.

Due to the system’s properties and its ability to be optimised for a wide variety of experiments, it is anticipated to promote a variety of drug discovery research.

“PURESYSTEM is one of the useful technologies and we will aggressively utilise [it] for the global development of antibody drugs. We are placing high hopes on the outcomes of using this […] technology.” Dr Hisafumi Okabe, vice-president and general manager of Chugai’s research division.

In November, Chugai announced the launch of its latest corporate advertisement, which aims to inform its audience about the company’s current mission statement.

This marked the first time the firm has altered its corporate advertisement since 2005.